Biosimilar butterflies and myths
This article was originally published in Scrip
Executive Summary
As the biosimilars debate in the United States gains momentum, some new data from Gaucher's and Fabry's diseases patients receiving replacements for their enzyme deficiency ought, in a logical world, to quieten some elements. It probably won’t though.